TetraLogic Pharmaceuticals is a privately held company focused on the discovery and development of important drugs to treat cancer. TetraLogic’s founding scientists, Drs. George McLendon and Yigong Shi, at Princeton University, discovered TetraLogic’s core technology which enables drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells. Since establishing operations during July 2004, TetraLogic scientists have produced drug candidates called IAP antagonists or Smac-mimetics that unblock apoptosis and kill cancer cells. The drug candidates may be useful to treat many types of cancer and have entered preclinical pharmacokinetic, toxicology and efficacy animal studies.